Sign up to be notified about Rayaldee news.

In addition to Rayaldee news, please

*Required field.

Message frequency may vary. You may opt out at any time.
Terms of Use and Privacy Policy

Financial Support

OPKO Connect services

How to enroll patients

Forms and resources

Frequently asked questions

Connecting your patients to access solutions

OPKO Connect service offerings wheel

OPKO Connect is a patient reimbursement hub offering support for your office on behalf of your patients who have been prescribed Rayaldee®.

For more information, watch the financial support videos on the Rayaldee Videos page:

Browse video library

It's simple. We can help. We care.

OPKO Connect services

General Support/Assistance

OPKO Connect can provide general support services such as:

  • Assisting with questions related to the product, program, or insurance coverage
  • Finding non-profit financial assistance
  • Resolving claims submission issues
Benefits Investigation

OPKO Connect will verify the patient’s insurance coverage for Rayaldee including identifying:

  • Prior authorization requirements
  • Deductible, co-insurance, and out-of-pocket costs
Prior Authorization (PA) Assistance

OPKO Connect will assist with any insurance-required PAs for Rayaldee by:

  • Providing the appropriate insurance-specific PA form to the healthcare provider’s office with instructions on how to complete and submit the form to insurance
  • Confirming insurance received the PA submission from the healthcare provider's office and following up with insurance to confirm status
  • Communicating the insurance PA determination to the patient and their healthcare provider's office
Support for Appeals if the PA Is Denied

OPKO Connect will:

  • Provide the healthcare provider's office a letter of medical necessity (LMN) template for the appeal with instructions on how to complete and submit the LMN to insurance
  • Confirm insurance received the appeal submission from the healthcare provider's office and follow up with insurance to confirm status
  • Communicate the insurance determination to the patient and their healthcare provider's office
Copay Assistance
Zero dollars

Eligible commercially insured patients can fill their Rayaldee prescription for $0.*

* Eligible commercially insured patients can fill their Rayaldee prescription for $0 with eVoucherRx™, a program from RelayHealth that automatically applies copay savings at the patient’s pharmacy. If the patient’s pharmacy does not work with RelayHealth eVoucherRx™, then OPKO Connect has a $0 copay program for eligible commercially insured patients. Call OPKO Connect at 1-844-414-OPKO (6756) for assistance.
Patient Assistance Program (PAP)

For patients without Rayaldee pharmacy insurance coverage, OPKO Connect has a patient assistance program offering free medication. Eligibility criteria apply and annual reenrollment is required.

Download the application for patient assistance below.

How to enroll patients

Start by sending a completed Rayaldee Service Request Form (SRF) to OPKO Connect or sending a prescription to your preferred specialty pharmacy.

1-844-660-7083 (fax)

Contact us for assistance

OPKO Connect services are available

Monday – Friday, 8 am – 8 pm ET

1-844-414-OPKO (6756)

Find the answers to some of the most frequently asked questions.

Forms and resources

PDF image of form
Rayaldee Service Request Form (SRF)
Download
PDF image of form
Patient Assistance Program (PAP) application
English Spanish Mandarin
PDF image of form
TRICARE coverage for Rayaldee flyer
Download
PDF image of form
TRICARE Pharmacy Program medical necessity form for Rayaldee
Download
PDF image of form
Attestation letter for patients with vitamin D insufficiency
Download
PDF image of form
Rayaldee letter of medical necessity
Download
PDF image of form
Part D Low-Income Subsidy Patients identification flashcard
Download
PDF image of form
OPKO Connect brochure
Download

Frequently Asked Questions

Common questions related to OPKO Connect and financial assistance for Rayaldee.

OPKO Connect is a centralized resource dedicated to helping patients access Rayaldee as quickly and easily as possible.

OPKO Connect offers many services to patients, such as:

  • Benefits investigation
  • Prior Authorization (PA) assistance
  • Appeals support
  • Copay assistance
  • Patient Assistance Program (PAP)

To further explore financial assistance options available, you can download a brochure or watch a video.

To receive support for your patients, start by completing a Rayaldee Service Request Form (SRF). Then email it to opkoconnect@rxallcare.com or fax it to 1-844-660-7083.

A patient’s out-of-pocket cost for Rayaldee depends on what type of coverage they have. At OPKO Connect, we can assist you with investigating a patient’s insurance coverage and benefit design for Rayaldee. Start by completing a Rayaldee Service Request Form (SRF) and emailing it to opkoconnect@rxallcare.com or faxing it to 1-844-660-7083.

Download a template for a letter of medical necessity to provide to your patient’s insurance company.

For patients without pharmacy insurance coverage or patients unable to afford their Rayaldee copay, OPKO Connect has a Rayaldee Patient Assistance Program (PAP) that offers free medication. Start by completing a Rayaldee Service Request Form (SRF) and emailing it to opkoconnect@rxallcare.com or faxing it to 1-844-660-7083.

Important Safety Information

• Hypercalcemia: Excessive administration of vitamin D compounds, including Rayaldee, can cause hypercalcemia and hypercalciuria. Severe hypercalcemia due to substantial overdosage of vitamin D and its metabolites may require emergency attention. Patients should be informed about the symptoms of elevated calcium.
• Digitalis toxicity: Potentiated by hypercalcemia of any cause. Monitor serum calcium and signs and symptoms of digitalis toxicity more frequently when initiating or adjusting the dose of Rayaldee.
• Adynamic Bone Disease: Monitor for abnormally low levels of intact parathyroid hormone (iPTH) levels when using Rayaldee, and adjust dose if needed.
• The most common adverse reactions (≥3% and more frequent than placebo) were anemia, nasopharyngitis, increased blood creatinine, dyspnea, cough, congestive heart failure and constipation.
• Care should be taken while dosing Rayaldee with cytochrome P450 inhibitors, thiazides, cholestyramine or drugs stimulating microsomal hydroxylation due to the potential for drug interactions.
• Serum calcium should be below 9.8 mg/dL before initiating treatment.
• Monitor serum calcium, phosphorus, 25-hydroxyvitamin D and iPTH 3 months after starting therapy or changing dose.

Please see Full Prescribing Information.

Indication and Limitations of Use

Rayaldee® (calcifediol) extended-release 30 mcg capsules is indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. Rayaldee is not indicated in patients with stage 5 chronic kidney disease or end-stage renal disease on dialysis.

Important Safety Information

• Hypercalcemia: Excessive administration of vitamin D compounds, including Rayaldee, can cause hypercalcemia and hypercalciuria. Severe hypercalcemia due to substantial overdosage of vitamin D and its metabolites may require emergency attention. Patients should be informed about the symptoms of elevated calcium.
• Digitalis toxicity: Potentiated by hypercalcemia of any cause. Monitor serum calcium and signs and symptoms of digitalis toxicity more frequently when initiating or adjusting the dose of Rayaldee.
• Adynamic Bone Disease: Monitor for abnormally low levels of intact parathyroid hormone (iPTH) levels when using Rayaldee, and adjust dose if needed.
• The most common adverse reactions (≥3% and more frequent than placebo) were anemia, nasopharyngitis, increased blood creatinine, dyspnea, cough, congestive heart failure and constipation.
• Care should be taken while dosing Rayaldee with cytochrome P450 inhibitors, thiazides, cholestyramine or drugs stimulating microsomal hydroxylation due to the potential for drug interactions.
• Serum calcium should be below 9.8 mg/dL before initiating treatment.
• Monitor serum calcium, phosphorus, 25-hydroxyvitamin D and iPTH 3 months after starting therapy or changing dose.

Please see Full Prescribing Information.